Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: biosimilar

Refocus Your Practice with Invigorating Sessions in San Diego

From the College  |  August 2, 2017

The landscape of practice management and coding methodologies continues to be challenging in the current healthcare environment, and rheumatology practices must maintain focus on managing an effective and efficient practice. Join us at the 2017 ACR/ARHP Annual Meeting, Nov. 3–8 in San Diego, and gain knowledge and understanding of best practices in an ever-changing environment…

Filed under:Education & TrainingFrom the CollegeProfessional Topics Tagged with:2017 ACR/ARHP Annual MeetingCommittee on Rheumatologic Care (CORC)

racorn/shutterstock.com

EULAR Releases 2016 Recommendations on RA Management

Mary Beth Nierengarten  |  July 14, 2017

Management of rheumatoid arthritis (RA) is complex. The ever-expanding availability of new drugs requires that rheumatologists and patients constantly consider treatment strategies and targets aimed at both disease control and symptom relief while remaining cognizant of the increasing high cost of emerging medications. Given such complexity, guidelines to inform rheumatologists about the most recent developments…

Filed under:ConditionsEULAR/OtherMeeting ReportsRheumatoid Arthritis Tagged with:drug therapyEULAREuropean League Against RheumatismManagementpatient carerecommendationsRheumatic DiseaseRheumatoid arthritisTreatment

ACR Pushes for Patient Interests, Against Spending Cuts

Angus Worthing, MD, FACP, FACR  |  July 5, 2017

Greetings from Washington, D.C. Your advocacy team had another busy month. Unlike my prior updates, and in order to keep our focus on health policy, I avoid mentioning anything about Washington investigations into obstruction of justice, collusion, etc. You get enough of that elsewhere. The Healthcare Bill Obamacare repeal and reform efforts are speeding up….

Filed under:EULAR/OtherFrom the CollegeLegislation & AdvocacyMeeting ReportsProfessional Topics Tagged with:ACR advocacyAlliance for Transparent & Affordable Prescriptions (ATAP)alternative payment models (APMs)BiosimilarsEULARMedPacMIPSObamacare repealpharmacy benefit managers (PBMs)Washington D.C. update

The Birth and Growth of Biotechnology, and the Impact of Biologic Drugs on Rheumatology

Simon M. Helfgott, MD  |  June 15, 2017

Here’s a trivia question: Where were the big ideas for the field of biotechnology first discussed? Answer: At a since-demolished delicatessen in Waikiki Beach, Hawaii. Go figure. The year was 1972, and Stanley Cohen, MD, professor of medicine at Stanford University in Palo Alto, Calif., and Herbert Boyer, PhD, a former professor and biochemist at the…

Filed under:Biologics/DMARDsOpinionResearch RheumRheuminationsSpeak Out Rheum Tagged with:BiologicsBiosimilarsbiotechnologyCongressDNAdrug costdrug therapypatient careResearchRheumatic DiseaserheumatologistrheumatologyTreatment

Sanofi to Invest Further in Biologics

Matthias Blamont  |  June 14, 2017

PARIS (Reuters)—Sanofi announced plans to invest 600 million euros ($673 million) annually over the next two to three years in the field of biologics production, an area of strong growth potential. In contrast to most drugs that are chemically synthesized, many biologics are produced using living cells. They are seen as a promising answer in…

Filed under:Biologics/DMARDsDrug Updates Tagged with:BiologicsSanofi

Rheumatologists Concerned High Healthcare Costs May Encourage Patients to Forgo, Delay Treatment

Susan Bernstein  |  June 14, 2017

While members of Congress debate healthcare legislation, rheumatologists say many of their patients struggle to afford everything from generic drugs to insurance copayments for physical therapy. “It’s a mess. The cost of prescriptions and the rationale for those rising costs in the U.S. right now—it’s just a mess,” says James R. O’Dell, MD, Stokes-Shackleford Professor of…

Filed under:Practice Support Tagged with:BiologicsBiosimilarsCompliancecostsdruggenericHealthcareMedicationpatient careRheumatic DiseaserheumatologistTreatment

U.S. Supreme Court Speeds Copycat Biologic Drugs to Market

Andrew Chung  |  June 13, 2017

WASHINGTON (Reuters)—The U.S. Supreme Court on Monday cut the time it will take for copycat versions of biologic drugs to get to the market in a pivotal ruling about an expensive class of medicines that can yield billions of dollars in sales for drug companies. The justices, in a 9–0 ruling, overturned a lower court…

Filed under:Biologics/DMARDsDrug Updates Tagged with:BiologicsBiologics & BiosimilarsBiosimilarsLegalSupreme CourtU.S. Supreme Court

Heart Safety Clouds Hopes for Amgen, UCB Bone Drug Approval

Bill Berkrot & Ben Hirschler  |  May 23, 2017

(Reuters)—Amgen Inc. and UCB SA no longer expect their experimental osteoporosis drug to win U.S. approval this year after a higher rate of serious heart-related side effects were observed in a late-stage clinical trial. The drug, romosozumab, which would be sold under the brand name Evenity if approved, is awaiting an approval decision by the…

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:FDAFood and Drug AdministrationOsteoporosisromosozumab

ACR Holds Its Ground Amid Rapid-Fire Changes in D.C.

Angus Worthing, MD, FACP, FACR  |  May 19, 2017

Greetings from your advocacy team in Washington, D.C.! The tectonic plates of the U.S. political landscape continue to shift. The latest: President Trump fired FBI Director James Comey on Tuesday, May 16; since then, Congress and journalists have had very little bandwidth for much else. But healthcare advocates remember just several news cycles ago when…

Filed under:From the CollegeLegislation & AdvocacyProfessional Topics Tagged with:ACR Capitol Hill visitAmerican Health Care Act (AHCA)Angus WorthingHealthcare updateObamacare

Fellows’ Forum: Why Rheumatology Fellows Should Get Involved with Advocacy

Alexandra Perel-Winkler, MD, & Christopher A. Mecoli, MD  |  May 16, 2017

Introduction Interest in rheumatology continues to grow, with more than 240 new adult and pediatric fellows to begin their training in the coming academic year. Given the broad and diverse career opportunities, it is an ACR goal to help guide trainees in their career decisions and professional development. Rheumatology fellowship often marks the transition from…

Filed under:Legislation & Advocacy Tagged with:AC&RAdvocacyAmerican College of Rheumatology (ACR)Capitol HillCongressEducationFellowsFellows ForumFundingLegislationpolicyrheumatologistRheumPAC

  • « Previous Page
  • 1
  • …
  • 30
  • 31
  • 32
  • 33
  • 34
  • …
  • 42
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences